The complement pathway is associated with loss of white matter microstructural integrity (LOWMI) and presents a potential therapeutic target amenable to modulation.
Why this matters
Age-related LOWMI is a strong contributor to cognitive decline, dementia, and gait disorders, as well as being associated with other neurodegenerative pathologies. However, the pathology behind these changes is unclear.
Genome-wide association studies (GWAS) may narrow down the candidate gene loci involved in age-related LOWMI, which can then be further investigated in functional studies.